A promising approach to target drug-resistant tumor cells is the use of oncolytic adenoviruses, specific for the oncogenic protein YB-1. Due to mutations in essential genome regions, these viruses induced a higher degree of apoptosis than wild type viruses. The oncolytic viruses triggered an immunogenic cell death in vitro and in vivo and elicited recruitment of dendritic cells and T cells, known contributors to the success of adenoviral therapy. The oncolytic viruses slightly reduced tumor growth and besides induction of anti-viral immunity, also elicited anti-tumor immune reactivity.
«
A promising approach to target drug-resistant tumor cells is the use of oncolytic adenoviruses, specific for the oncogenic protein YB-1. Due to mutations in essential genome regions, these viruses induced a higher degree of apoptosis than wild type viruses. The oncolytic viruses triggered an immunogenic cell death in vitro and in vivo and elicited recruitment of dendritic cells and T cells, known contributors to the success of adenoviral therapy. The oncolytic viruses slightly reduced tumor grow...
»